TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

Official record

Identifier

NCT07713732

Recruiting locations

country

Australia

Interventions studied

TLN-499Venetoclax

Lead sponsor

Treeline Biosciences, Inc.

Target enrolment

120 participants

Study type

INTERVENTIONAL

Phase

Phase 1

Status

Recruiting

First posted

Jul 20, 2026

Last updated on the registry

Oct 1, 2026

Age

18 Years

Sex

ALL

Study contact

The official record lists a study contact. Contact details are published there and are intentionally not copied to this page.

Eligibility criteria

Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.

Inclusion Criteria:

1. Adults ≥18 years of age
2. Histologically confirmed relapsed/refractory SCLC, neuroendocrine cancer, malignant pleural mesothelioma, or synovial sarcoma
3. Measurable disease per RECIST v1.1 or mRECIST
4. ECOG performance status 0-1
5. Adequate hematologic, hepatic, renal, and coagulation function.
6. Life expectancy ≥12 weeks
7. Signed informed consent

Exclusion Criteria:

1. Active brain metastases
2. Major surgery or severe trauma within 4 weeks before first dose
3. Significant uncontrolled medical conditions preventing study participation
4. Use of prohibited concomitant medications
5. Previous conditions that would interfere with study assessments or safety

Indexed under

Lung Cancer